AQR Capital Management LLC Invests $753,000 in Xencor, Inc. (NASDAQ:XNCR)

AQR Capital Management LLC bought a new stake in Xencor, Inc. (NASDAQ:XNCR - Free Report) during the 2nd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund bought 39,791 shares of the biopharmaceutical company's stock, valued at approximately $753,000. AQR Capital Management LLC owned approximately 0.06% of Xencor as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also made changes to their positions in the company. Vanguard Group Inc. boosted its stake in shares of Xencor by 1.7% in the fourth quarter. Vanguard Group Inc. now owns 6,767,249 shares of the biopharmaceutical company's stock valued at $143,669,000 after buying an additional 115,886 shares in the last quarter. Los Angeles Capital Management LLC acquired a new position in shares of Xencor during the 1st quarter worth $229,000. GAMMA Investing LLC grew its stake in shares of Xencor by 153.7% during the 1st quarter. GAMMA Investing LLC now owns 2,172 shares of the biopharmaceutical company's stock worth $48,000 after purchasing an additional 1,316 shares during the period. Diversified Trust Co increased its holdings in shares of Xencor by 4.5% in the 1st quarter. Diversified Trust Co now owns 13,059 shares of the biopharmaceutical company's stock valued at $289,000 after purchasing an additional 563 shares in the last quarter. Finally, China Universal Asset Management Co. Ltd. lifted its stake in shares of Xencor by 67.0% in the first quarter. China Universal Asset Management Co. Ltd. now owns 11,755 shares of the biopharmaceutical company's stock valued at $260,000 after purchasing an additional 4,714 shares during the period.

Analyst Upgrades and Downgrades

A number of research analysts have issued reports on the stock. BMO Capital Markets reaffirmed an "outperform" rating and issued a $32.00 target price on shares of Xencor in a report on Tuesday, August 6th. Wedbush reaffirmed an "outperform" rating and issued a $34.00 price objective on shares of Xencor in a research note on Monday, September 9th. Royal Bank of Canada boosted their target price on Xencor from $31.00 to $34.00 and gave the stock an "outperform" rating in a research report on Thursday, September 26th. Finally, JPMorgan Chase & Co. dropped their price target on Xencor from $30.00 to $27.00 and set an "overweight" rating for the company in a research report on Wednesday, July 31st. Two investment analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has issued a strong buy rating to the company's stock. According to data from MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and a consensus price target of $34.78.

Xencor Price Performance

Shares of XNCR traded down $0.26 during trading hours on Monday, reaching $21.03. 299,199 shares of the company traded hands, compared to its average volume of 619,937. The stock has a market capitalization of $1.30 billion, a PE ratio of -9.82 and a beta of 0.67. The stock has a fifty day simple moving average of $18.53 and a 200 day simple moving average of $20.12. Xencor, Inc. has a fifty-two week low of $15.31 and a fifty-two week high of $26.84. The company has a quick ratio of 6.92, a current ratio of 6.92 and a debt-to-equity ratio of 0.02.

Xencor (NASDAQ:XNCR - Get Free Report) last released its quarterly earnings results on Monday, August 5th. The biopharmaceutical company reported ($1.07) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.82) by ($0.25). The firm had revenue of $16.96 million for the quarter, compared to analyst estimates of $21.13 million. Xencor had a negative return on equity of 28.23% and a negative net margin of 132.74%. Xencor's revenue for the quarter was down 62.7% on a year-over-year basis. During the same period in the prior year, the business earned ($0.37) earnings per share. As a group, research analysts predict that Xencor, Inc. will post -4.15 EPS for the current fiscal year.

About Xencor

Xencor, Inc, a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases. The company provides Sotrovimab that targets the SARS-CoV-2 virus; Ultomiris for the treatment of patients with paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome; and Monjuvi for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma.